<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843943</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-156(2)R</org_study_id>
    <nct_id>NCT04843943</nct_id>
  </id_info>
  <brief_title>Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC</brief_title>
  <official_title>An Exploratory Study of Sintilimab in Combination With Bevacizumab Biosimilar in Patients With Potentially Resectable Intermediate HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with&#xD;
      bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular&#xD;
      carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0; Surgical safety including Intraoperative blood loss，PHLF assessed by ISGLS（2012），Postoperative complications evaluated by modified Clavien-Dindo system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Events Free Survival (EFS) Assessed by RECIST1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from enrollment to disease progression, recurrence or death (whichever occurs first)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>resection rate (R0 resection rate)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients undergoing radical resection to the total subjects (R0 resection rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients who had pathological response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) assessed by RECIST1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival (RFS) of patients who accepted surgery</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from the date of surgery to the date of disease recurrence or death whichever occur first, assessed up to 2 years post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) assessed by RECIST1.1 of patients who didn't accept surgery</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of the patients who accepted surgery</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from the date of treatment start to the date of death or to the date of last follow-up for patients alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of the patients who didn't accepted surgery</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from the date of treatment start to the date of death or to the date of last follow-up for patients alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from the date of treatment start to the date of death or to the date of last follow-up for patients alive</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab: 200mg IV Q3W D1</description>
    <arm_group_label>Sintilimab+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab Biosimilar</intervention_name>
    <description>Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1</description>
    <arm_group_label>Sintilimab+Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide informed consent and willing to sign an approved consent form&#xD;
&#xD;
          2. Age 18-75, male and female&#xD;
&#xD;
          3. Potentially resectable Intermediate (CNLC-IIa and IIb) HCC with diagnosis confirmed by&#xD;
             histology/cytology or clinically&#xD;
&#xD;
          4. No prior therapy for HCC&#xD;
&#xD;
          5. Child-Pugh: A&#xD;
&#xD;
          6. ECOG PS: 0-1&#xD;
&#xD;
          7. Expected survival ≥6 months&#xD;
&#xD;
          8. Measurable disease per RECIST1.1&#xD;
&#xD;
          9. Major organ functions meet the following requirements:&#xD;
&#xD;
             no blood transfusion, no use of hematopoietic stimulators (including g-csf, gm-csf,&#xD;
             EPO and TPO) and infusion of human albumin preparations within 14 days prior to&#xD;
             screening: neutrophil absolute count ≥1.0×10^9/L;Platelet count ≥ 75×10^9/L;Hemoglobin&#xD;
             ≥ 9 g/dL;Serum albumin ≥ 2.8 g/dL;Total serum bilirubin ≤2.0× upper limit of normal&#xD;
             range (ULN);Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 ×&#xD;
             ULN;Serum creatinine (Cr) ≤1.5×ULN or Cr clearance ≥30 mL/min (calculated by&#xD;
             Cockcroft-Gault formula);International standardized ratio (INR) ≤1.5×ULN;&#xD;
&#xD;
         10. Women of childbearing age must undergo a blood pregnancy test within the first 3 days&#xD;
             of randomization with negative results and agree to use a reliable and effective&#xD;
             method of contraception during the trial and within 120 days of the last trial drug&#xD;
             administration. Male patients whose partners are women of childbearing age must agree&#xD;
             to use a reliable and effective method of contraception during the trial and within&#xD;
             120 days of the last trial drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. known as cholangiocarcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid&#xD;
             hepatocellular carcinoma, and hepatic fibrolamellar carcinoma.&#xD;
&#xD;
          2. History of organ transplantation or hepatic encephalopathy&#xD;
&#xD;
          3. Tumor accumulation range exceeds 70% of liver volume&#xD;
&#xD;
          4. Pleural fluid, ascites, and pericardial effusion with clinical symptoms requiring&#xD;
             drainage&#xD;
&#xD;
          5. Any history of kidney disease or nephrotic syndrome&#xD;
&#xD;
          6. History of gastrointestinal (GI) perforation and/or fistula in the past 6&#xD;
             months;Severe (G3) varicose veins are known to be present on endoscopy within 3 months&#xD;
             before the first dose ; history of thrombosis, bleeding diathesis, coagulopathy or&#xD;
             significant vascular disease&#xD;
&#xD;
          7. Prior life-threatening blood loss or grade 3/4 gastrointestinal bleeding requiring&#xD;
             blood infusion, endoscopic or surgical intervention within 3 months&#xD;
&#xD;
          8. Arterial and venous thromboembolic events in the past 6 months, including myocardial&#xD;
             infarction, unstable angina, cerebrovascular accident or transient ischemic attack,&#xD;
             pulmonary embolism, deep vein thrombosis or any other serious thromboembolism history.&#xD;
&#xD;
          9. Severe bleeding tendency or coagulopathy, or are receiving thrombolytic therapy&#xD;
&#xD;
         10. Long-term use of vitamin K antagonists (such as warfarin) or low-dose&#xD;
             low-molecular-weight heparin (such as enoxaparin 40 mg/day) or heparin&#xD;
&#xD;
         11. Uncontrollable hypertension, systolic blood pressure&gt; 140 mmHg or diastolic blood&#xD;
             pressure&gt; 90 mmHg after optimal medical treatment, history of hypertensive crisis or&#xD;
             hypertensive encephalopathy&#xD;
&#xD;
         12. Symptomatic congestive heart failure (New York Heart Association Grade II-IV),&#xD;
             symptomatic or poorly controlled arrhythmia, history of congenital long QT syndrome or&#xD;
             QTc&gt; 500ms corrected during screening&#xD;
&#xD;
         13. History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation,&#xD;
             or intra-abdominal abscess within 6 months of initiation of study treatment&#xD;
&#xD;
         14. Had major surgical procedure within 4 weeks of initiation of study treatment&#xD;
&#xD;
         15. Past and current history of pulmonary fibrosis, interstitial pneumonia,&#xD;
             pneumoconiosis, drug-related pneumonia, severely impaired lung function and other lung&#xD;
             diseases&#xD;
&#xD;
         16. Had acute or chronic active hepatitis B or C infection. Hepatitis C virus (HCV)&#xD;
             RNA&gt;103 copies/ml; hepatitis B surface antigen (HbsAg) and anti-HCV antibody are&#xD;
             positive at the same time; hepatitis B virus (HBV) DNA positive but has received&#xD;
             antiviral treatment is allowed.&#xD;
&#xD;
         17. Had active tuberculosis (TB)&#xD;
&#xD;
         18. Had human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive), known&#xD;
             syphilis infection&#xD;
&#xD;
         19. Had severe infections that are active or poorly clinically controlled.&#xD;
&#xD;
         20. Had active autoimmune disease&#xD;
&#xD;
         21. Have used immunosuppressive drugs within 4 weeks before the first dose&#xD;
&#xD;
         22. Received live attenuated vaccines within 4 weeks before the first dose or plan to&#xD;
             receive live attenuated vaccines during the study period&#xD;
&#xD;
         23. Received Chinese medicine with anti-tumor indications, or received drugs with&#xD;
             immunomodulatory effect within 2 weeks before the first administration&#xD;
&#xD;
         24. Received any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA4 antibody, or other&#xD;
             immunotherapy&#xD;
&#xD;
         25. Allergic to Sintilizumab, Bevacizumab preparations and excipients, or had severe&#xD;
             allergic reactions to other monoclonal antibodies in the past&#xD;
&#xD;
         26. Received treatment from other clinical trials within 4 weeks before the first dose&#xD;
&#xD;
         27. Female patients who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huichuan Sun</last_name>
    <phone>13701922065</phone>
    <email>sun.huichuan@zs-hospital.sh.cn</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jia Fan</investigator_full_name>
    <investigator_title>Director of hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

